Last reviewed · How we verify
allogeneic platelet plasma
Allogeneic platelet plasma, marketed by Peking University Third Hospital, holds a unique position in the therapeutic landscape, though specific revenue figures are not disclosed. The drug's key strength lies in its allogeneic formulation, which may offer broader applicability and reduced patient-specific preparation times compared to autologous alternatives. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | allogeneic platelet plasma |
|---|---|
| Sponsor | Peking University Third Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients (NA)
- Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial (PHASE4)
- Outcomes of Patient Blood Management in Patients Undergoing Major Surgery
- Allogeneic Platelet Rich Plasma (PRP) to Treat Diabetic Foot Ulcers (PHASE1, PHASE2)
- Persistent Pleural Effusion Treatment Following Cardiothoracic Surgery by Platelet-Fibrin Glue (PHASE2)
- Outcomes of Patient Blood Management in Severely Anemic Patients
- MSCs for the Treatment of Burn Wounds (PHASE1, PHASE2)
- Transplantation of Bone Marrow Mesenchymal Stromal Cells for Periodontal Regeneration (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- allogeneic platelet plasma CI brief — competitive landscape report
- allogeneic platelet plasma updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI